David O'Hagan

Organic Chemistry · 2000–2010

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 10 researchers here, as inferred from the citation graph.

Subfields

Whom David O'Hagan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. I. Ojima

Who trusts David O'Hagan overall

  1. S. Swallow
  2. O. Tomashenko
  3. D. Chopra
  4. N. Meanwell
  5. J. Gardiner
  6. G. Knizia

Papers from David O'Hagan's perspective

Ordered by how strongly the researchers David O'Hagan trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Systematic identification of genomic markers of drug sensitivity in cancer cells (Nature)
  2. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (Nature Communications)
  3. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. (Cancer Research)
  4. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth (Cell)
  5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  6. Mutational signatures associated with tobacco smoking in human cancer (Science)
  7. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing (Proceedings of the National Academy of Sciences of the United States of America)
  8. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (The Lancet Oncology)
  9. Cancer burden in the year 2000. The global picture. (European Journal of Cancer)
  10. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)

Their papers